Compare GDHG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDHG | TVRD |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | China | United States |
| Employees | N/A | 12 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 34.6M |
| IPO Year | 2022 | N/A |
| Metric | GDHG | TVRD |
|---|---|---|
| Price | $1.77 | $2.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 4.4K | ★ 45.6K |
| Earning Date | 07-11-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $2.75 |
| 52 Week High | $8.69 | $43.65 |
| Indicator | GDHG | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 34.12 |
| Support Level | $1.53 | N/A |
| Resistance Level | $1.98 | $4.32 |
| Average True Range (ATR) | 0.17 | 0.29 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 9.52 | 2.34 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.